anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Globus pharyngeus is a clinical condition, wherein, a patient senses a lump or a foreign body in the throat with a tightening or choking feeling. A strong association between globus pharyngeus and gastroesophageal reflux disease (GERD) was reported. Therefore, we sought to investigate the predictive factors of globus pharyngeus in patients with established GERD and fit a predictive scoring model for globus pharyngeus.
METHODS: In this case-control study, 143 patients having globus pharyngeus along with GERD ( case ) and 109 patients having globus pharyngeus without GERD ( control ) were enrolled. Data comprising demographics, comorbidities, and psychosocial stress levels were recorded. The predictive factors of globus pharyngeus in patients with GERD were unraveled, and a predictive scoring model was fit for globus pharyngeus.
RESULTS: Proton pump inhibitor usage in the case group was significantly higher compared to controls (63.63% vs 24.78%, P < 0.001), and differences in Hiatus Hernia and Stress levels were highly significant between the two groups ( P < 0.001). Multivariate logistic regression revealed that variates, Hiatus Hernia, psychosocial stress, and age were highly significant ( P < 0.001) independent predictors of globus pharyngeus. Using the regression coefficients of all the independent predictor variables, a predictive scoring model was fitted, which yielded an area under receiver operating characteristic (AUROC) curve of 78.9.
CONCLUSION: Hiatus hernia, psychosocial stress, and age are significant independent predictors of globus pharyngeus in GERD, and our predictive scoring model may help in identifying patients at higher odds of experiencing globus pharyngeus and modulate treatment accordingly.
The utility model relates to a hydrophilic adhesive material pasting film capable of absorbing the skin nutrient and the drug. The utility model is sequentially connected with an isolating layer, a hydrophilic biology adhesion material drug bin layer and a fabric bottom liner layer from exterior to interior. The isolating layer is made of the plastic film which is pressed with the pattern or the release paper. The thickness of the drug bin layer is 1 mm to 5mm, and the drug bin layer is provided with the sterile water or is absorbed with the skin nutrient and the transdermal drug. The shape of the product is the mask shape fit for the face, the ellipse fit for the upper and the lower eyelids of the human body, or the general geometric shape. Compared with the prior art, the utility model has the advantages that the structure is novel; as the hydrophilic biology adhesion material drug bin layer is adopted, the drug bin layer can be provided with multiple function substances for nursing and nourishing the skin, or the transdermal absorption drug; the permeability is strong; the moist characteristic is good; the skin is nourished, and the horniness is softened.
This study is a single-centre observational study to train, internally validate, and test an AI-driven 3D camera weight estimation system. Our hypothesis is that this system, when used in the management of acutely ill patients, will be able to estimate total body weight, ideal body weight, and lean body weight more accurately than other current point-of-care system. Healthy volunteers will be used to train and test the system. During a single data collection session of approximately 30 minutes, baseline anthropometric data, a DXA scan, and 3D camera images of volunteers lying on a medical stretcher will be captured. There will be no interventions, and no follow up of participants. The collected data will be used to train an AI algorithm (based on artificial neural networks) to estimate weight using a single depth image. Once the AI system is fully evolved, the accuracy of its weight estimation performance will be evaluated in an independent test dataset.
Participants will receive coded non-transparent bottles of Previfenon®, each containing 90 EGCG capsules (250 mg per capsule plus excipients) The total EGCG dose per patient will be 750 mg/day (3 capsules) for 40 consecutive days as minimum or a maximum variable time between 60 to 70 days. It will be divided into three daily intakes of one capsule of Previfenon® every 8 hours.
The invention provides identification and alignment of multiple marker fixtures. The invention discloses performing an alignment coordinate system on an image by positioning a calibration fixture having at least two collinear marker quadruples that are opaque to an imaging modality. Collinear quadruples are detected on the image of the jig and the corresponding image cross-ratios of the collinear quadruples are calculated. Candidate lines are established by correlating at least one collinear marker quadruple and at least one collinear image quadruple having a matched cross-ratio. Using the pairs of candidate lines, a corresponding alignment of the calibration jig is performed using the image. One of the alignments is selected, where the selected alignment has a residue that is less than a predetermined value.
The invention relates to an ordered mesoporous microsphere medicine carrier with bioactivity and a preparation method thereof. The preparation method comprises the following steps of: preparing ethanol-water-in-oil emulsion containing oxides of SiO2, CaO and P2O3 by using an emulsion technology; and removing water and ethanol from the emulsion through rotary evaporation, ageing, and calcining to remove a template agent so as to obtain mesoporous microspheres with the bioactivity. The prepared mesoporous biological glass microspheres have controllable regular shapes, certain pore order, and adjustable pore diameter and specific surface area, and the surfaces of the microspheres can be chemically modified to improve medicine loading capacity, so that better medicine sustained-release effect is achieved. The calcium and phosphorus elements are introduced into the microspheres, so that the bioactivity of mesoporous silicon dioxide is greatly improved and the application requirement of bone tissue engineering is met. By combining the emulsion technology and an evaporation induced self-assembly method, the mesoporous structure which is ordered to some extent is obtained by controlling the ratio of the water to the ethanol in a dispersion phase. The method is simple and practicable, process and equipment requirements are lower, and experiment parameters are easy to control.
This invention creates compounds represented by the following formula (1) which, alone or as a plurality of them simultaneously, act upon serotonin receptors, and thereby provides pharmaceutical compositions that contain these compounds and are useful for the treatment or prevention of diseases which are considered to be induced by the abnormality of central and peripheral serotonin controlling functions. (see formula 1) In the formula, R1 is a hydrogen atom, a lower alkyl group or an aralkyl group; R2 is a hydrogen atom or a specified substituent; n is an integer of 2 to 6; and .alpha. is the following formula (a), (b), (c), (d) or (e). (see formula a) (see formula b) (see formula c) (see formula d) (see formula e) In formulae (a) and (b), R3 is a hydrogen atom or a specified substituent; X is NR10, NCONR11R12, S, SO, SO2 or O; R10 is a hydrogen atom or a specified substituent; R11 and R12 is independently a hydrogen atom or a lower alkyl; Y is a methylene group or a carbonyl group. In formula (c), R4 is a hydrogen atom or a specified substituent; R5 is a hydrogen atom or a specified substituent; k is 0 or an integer of 1 to 3; m is 0 or an integer of 1 to 3; each of A and B is a group which forms a specified ring via a double bond; k + m is an integer of 1 to 3. Informulae (d) and (e), R4 is as defined above; G is CH2, S, O or C=O; D is CH or N; p is an integer of 1 to 3; each of E and J is a group which forms a benzene ring or a pyridine ring via a double bond; R6 and R7 is independently a hydrogen atom or a lower alkyl or the like specified substituent.
For adults, colestipol hydrochloride tablets are recommended in doses of 2 grams/day to 16 grams/day given once or in divided doses. The starting dose should be 2 grams once or twice daily. Dosage increases of 2 grams, once or twice daily should occur at 1 month or 2 month intervals. Appropriate use of lipid profiles as per NCEP guidelines including LDL-C and triglycerides, is advised so that optimal but not excessive doses are used to obtain the desired therapeutic effect on LDL-C level. If the desired therapeutic effect is not obtained at a dose of 2 grams/day to 16 grams/day with good compliance and acceptable side effects, combined therapy or alternate treatment should be considered.

Colestipol hydrochloride tablets must be taken one at a time and be promptly swallowed whole, using plenty of water or other appropriate liquid. Do not cut, crush or chew the tablets. Patients should take other drugs at least one hour before or four hours after colestipol hydrochloride tablets to minimize possible interference with their absorption. (See Drug Interactions.)

Before Administration of Colestipol Hydrochloride Tablets

  1. Define the type of hyperlipoproteinemia, as described in NCEP guidelines.
  2. Institute a trial of diet and weight reduction.
  3. Establish baseline serum total and LDL-C and triglyceride levels.



During Administration of Colestipol Hydrochloride Tablets

  1. The patient should be carefully monitored clinically, including serum cholesterol and triglyceride levels. Periodic determinations of serum cholesterol levels as outlined in the NCEP guidelines should be done to confirm a favorable initial and long-term response.
  2. Failure of total or LDL-C to fall within the desired range should lead one to first examine dietary and drug compliance. If these are deemed acceptable, combined therapy or alternate treatment should be considered.
  3. Significant rise in triglyceride level should be considered as indication for dose reduction, drug discontinuation or combined or alternate therapy.
BACKGROUND: Cerebral autoregulation is impaired early on after aneurysmal subarachnoid hemorrhage (aSAH). The study objective was to explore the pressure reactivity index (PRx) and cerebral perfusion pressure (CPP) in the earliest phase after aneurysm rupture and to address the question of whether an optimal CPP (CPPopt)-targeted management is associated with less severe early brain injury (EBI).
METHODS: Patients with aSAH admitted between 2012 and 2020 were retrospectively included in this observational cohort study. The PRx was calculated as a correlation coefficient between intracranial pressure and mean arterial pressure. By plotting the PRx versus CPP, CPP correlating the lowest PRx value was identified as CPPopt. EBI was assessed by applying the Subarachnoid Hemorrhage Early Brain Edema Score (SEBES) on day 3 after ictus. An SEBES ≥ 3 was considered severe EBI.
RESULTS: In 90 of 324 consecutive patients with aSAH, intracranial pressure monitoring was performed ≥ 7 days, allowing for PRx calculation and CPPopt determination. Severe EBI was associated with larger mean deviation of CPP from CPPopt 72 h after ictus (r = 0.22, p = 0.03). Progressive edema requiring decompressive hemicraniectomy was associated with larger deviation of CPP from CPPopt on day 2 (r = 0.23, p = 0.02). The higher the difference of CPP from CPPopt on day 3 the higher the mortality rate (r = 0.31, p = 0.04).
CONCLUSIONS: Patients with CPP near to the calculated CPPopt in the early phase after aSAH experienced less severe EBI, less frequently received decompressive hemicraniectomy, and exhibited a lower mortality rate. A prospective evaluation of CPPopt-guided management starting in the first days after ictus is needed to confirm the clinical validity of this concept.
Patients will be given rectal metronidazole (Flagyl) 500 mg/dose for children weighing 10-14,9 kg, 1000 mg/dose for those weighing 15-29,9 kg and 1500 mg/dose for those weighing 30-44,9 kg. Suppositories will not be halved. Patients will be given 1 dose/day for 3 days.
The sham HBOT protocol consists of 6 weeks protocol including 5 daily sham HBOT sessions per week (total of 30), each session includes breathing 21% oxygen by mask in a sham multiplace chamber. Sham pressure will go up to 1.2 ATA during the first five minutes of the session (to stimulate the pressure sensation in the ears), and then decrease during the next 5 minutes to 1.03 ATA for 90 minutes with 5-minute air breaks every 20 minutes.
Objective. Polymorphism investigation of T786C gene promoter of endothelial nitric oxide synthase (eNOS/NOS3) in the arterial hypertension is a promising field for determining the relationship between heredity, hypertension, and dyslipidemia, which still remains controversial. The purpose of the study was to investigate the lipid profile, which depends on the NOS3 T786C gene promotor region polymorphism in patients with arterial hypertension. Methods. The study involved 86 patients with arterial hypertension. The control group consisted of 30 basically healthy individuals. The lipid profile in the blood serum of the studied patients was measured by commercially available kits using Biochem FC-200 analyzer (HTI, USA). The allelic polymorphism of NOS3 T786C gene promoter was studied using a polymerase chain reaction technique with electrophoretic detection of the results. Results. An increase at the level of all atherogenic fractions in the blood was found in the group of patients carrying the CC genotype compared with carriers of the TT genotype of the NOS3 gene. The total cholesterol serum level in the group of carriers of the CC genotype of NOS3 T786C gene promoter increased by 33.3% compared with carriers of the TT genotype and it was almost twice as high as the control values. In the group of carriers in the CC genotype of the NOS3 gene, the serum level of triglycerides was statistically significantly higher (2.9 times) than in the group of carriers of the TT genotype. The low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) serum levels significantly increased in patients with arterial hypertension with the CC genotype by 1.6 and 4.6 times, respectively, compared with the TT genotype carriers. The high-density lipoprotein (HDL) serum level, as an antiatherogenic factor, was statistically significantly lower (by 45.8%) in the group of the CC genotype carriers of the NOS3 gene than in the group with carriers of the TT genotype (0.58±0.06 vs. 1.07±0.03 mmol/l.) Conclusions. The increase in all atherogenic and decrease in antiatherogenic lipid parameters of the lipidogram of patients with arterial hypertension and the deepening of dyslipidemia in carriers of the CC genotype compared with carriers of the TT genotype of the NOS3 T786C gene promoter is crucial in the development of dyslipidemia.
Laparoscopic TAPP (Trans-Abdominal PrePeritoneal) is a minimally invasive surgical procedure used to repair inguinal hernias. Arguably, one important aspect to TAPP hernia repair is the identification of anatomical landmarks and the correct use of various laparoscopic instruments. There are very few studies regarding the use of artificial intelligence in laparoscopic inguinal hernia repair and more specifically in TAPP. The aim of this study is to evaluate the feasibility and usefulness of AI in the recognition of anatomical landmarks and tools in laparoscopic TAPP videos. Imaging data have been exported from 20 Laparoscopic TAPP videos that have been performed by the authors and another 5 high quality TAPP videos from the internet (free access) performed by other surgeons. In total 1095 selected images have been exported for annotation. To accomplish the AI result of computer vision, the YOLOv8 model of deep learning was used. In total 2716 segmented areas of interest have been exported. The AI model was able to detect the various classes with a maximum F1 score of .82 when the confidence threshold was set to .406. The mAP50 was .873 for all classes. The Precision was above 50% when the confidence was over 10%. The Recall rate was above 50% when confidence was less than 70%. These results suggest that the model is effective at balancing precision and recall, capturing both true positives and minimizing false negatives. Artificial Intelligence recognition of anatomical landmarks and laparoscopic instruments in TAPP is feasible with acceptable success rates.
An adsorbent for immunosuppressive substance, which can adsorb an excessive immunosuppressive substance directly from a body fluid, can carry out extracorporeal perfusion safely and can be utilized in treatment of cancer. The excessive immunosuppressive substance may be involved in growth of cancer cells. The adsorbent for immunosuppressive substance includes a water-insoluble carrier and a hydrophilic amino group immobilized to the water-insoluble carrier. An extracorporeal perfusion column contains the adsorbent of the invention. A method for treating cancer carries out extracorporeal perfusion using the extracorporeal perfusion column. A method of adsorbing the transforming growth factor β which is combined with another protein, includes adsorbing the transforming growth factor β and protein on an adsorbent containing a water-insoluble carrier to which quaternary ammonium groups each having 3 to 18 carbon atoms per one nitrogen atom are attached, and having a specific surface area of 0.1 m 2  or more per gram.
Risk Summary

There are no available data on OHTUVAYRE use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In animal reproduction studies, administration of inhaled ensifentrine at exposures 30 times the exposure at the maximum recommended human daily inhalation dose (MRHDID) to male rats for 10 weeks prior to mating with untreated females produced increased pre- and post- implantation loss, and decreased live embryos in untreated female rats. No adverse developmental effects were observed with inhalation administration of ensifentrine to pregnant rats and rabbits during organogenesis at maternal exposures up to 79 and 9 times the exposure at MRHDID, respectively. No adverse developmental effects were observed after inhaled administration of ensifentrine to pregnant rats from the period of organogenesis through lactation at exposures up to approximately 79 times the MRHDID. (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

In a male fertility study, ensifentrine was administered to male rats at inhalation doses of 2, 6, and 16 mg/kg/day (4, 13, and 30 times the exposure at the MRHDID) for 10 weeks prior to mating to untreated females. Adverse effects at 16 mg/kg/day (30 times the exposure at the MRHDID) on reproductive performance included increased pre- and post- implantation loss, and decreased live embryos per litter in untreated females. No developmental toxicity was observed in rats at 6 mg/kg/day (13 times the exposure at the MRHDID).

In an embryo-fetal development study, pregnant rats were administered ensifentrine at inhalation doses of up to 15 mg/kg/day (79 times the exposure at the MRHDID) during the period of organogenesis from gestation Days 6 to 17. Ensifentrine did not cause adverse effects to the fetus at exposures up to 79 times the MRHDID (on an AUC basis at a maternal inhalation dose of 15 mg/kg/day).

In an embryo-fetal development study, pregnant rabbits were administered ensifentrine at inhalation doses of up to 12 mg/kg/day (9 times the exposure at the MRHDID) during the period of organogenesis from gestation Days 6 to 19. Ensifentrine did not cause adverse effects to the fetus at maternal exposures up to 9 times the MRHDID.

In a pre- and post-natal development (PPND) study, pregnant rats were administered ensifentrine at inhalation doses of up to 19 mg/kg/day (approximately 79 times the exposure at the MRHDID) from gestation day 6 to lactation/post-partum day 24. No adverse effects were observed in the offspring exposed daily from birth (in utero) through lactation at maternal pulmonary deposited doses up to approximately 79 times the MRHDID.
Centella asiatica (L.) Urban is a famous Chinese traditional medicine, which is widely used for treating various chronic inflammatory diseases. Although there are reports that Centella total glycosides exhibit heart-protective properties, our previous experiment showed that it has cardiac toxic effects in zebrafish. The components of Centella total glycosides are complex, so we recommend further research to determine their key components and mechanisms. In this study, sample quantification was done using liquid chromatography-tandem mass spectrometry. The cardiotoxicity of Centella total glycosides, asiaticoside, madecassoside, asiatic acid, and madecassic acid was evaluated using zebrafish and cell models. The zebrafish oxidative stress model and myocarditis model were used to explore further the mechanisms through which cardiotoxicity is achieved. Asiatic acid and madecassic acid caused zebrafish cardiotoxicity and H9C2 cell death. However, no toxicity effects were observed for asiaticoside and madecassoside in zebrafish, until the solution was saturated. The results from the cell model study showed that asiatic acid and madecassic acid changed the expression of apoptosis-related genes in myocardial cells. In the zebrafish model, high concentrations of these components raised the levels of induced systemic inflammation, neutrophils gathered in the heart, and oxidative stress injury. Asiatic acid and madecassic acid are the main components causing cardiotoxicity in zebrafish. This may be due to enhanced inflammation and reactive oxygen species injury, which causes myocardial cell apoptosis, which further leads to cardiac toxicity.
This study tested the usability of a home-based self-administration transcranial direct current stimulation (tDCS) device designed specifically for women's health needs. This is a single center triple blinded clinical usability study for a new wireless, Bluetooth-controlled wearable tDCS device for women's health. The study aims to evaluate the usability and effective blinding of a home-based tDCS system. A total of forty-nine women of reproductive age were randomly allocated (1:1) to receive one session of active tDCS (n = 24) or sham tDCS (n = 25) over the motor and dorsolateral prefrontal cortex. Each participant self-administered one 20-minute session without supervision following guidance on a software application alone. The System Usability Scale (SUS) and the Patient Global Impression of Change (PGIC) were used to evaluate the usability of the system. Regardless of sham or active conditions, all users found the system easy to use without the support of researchers. Usability scores were considered to be "excellent" in both groups and no significant difference was found between sham and active groups showing effective blinding of the device (Active group: 93.7 (83.1-97.5); Sham group 90 (86.2-95) p = 0.79) and PGIC (Active group: 2 (1-2.75); Sham group 2 (1-2) p = 0.99) using an unpaired t-test or non-parametric statistical tests accordingly. The new Bluetooth-controlled wearable tDCS device is easy, safe to use and completely controlled by a smartphone app. This device is focused on women's health and will be tested as an alternative treatment for chronic pelvic pain and mood disturbance associated with menstrual cycles in further research.